Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Department of Stem Cell Therapy Science, Osaka University Graduate School of Medicine, Osaka, Japan.
PLoS One. 2020 Apr 10;15(4):e0230392. doi: 10.1371/journal.pone.0230392. eCollection 2020.
High-mobility group box 1 protein (HMGB1) fragment enhances bone marrow-derived mesenchymal stem cell (BM-MSC) recruitment to damaged tissue to promote tissue regeneration. This study aimed to evaluate whether systemic injection of HMGB1 fragment could promote tissue repair in a rat model of myocardial infarction (MI).
HMGB1 (n = 14) or phosphate buffered saline (n = 12, control) was administered to MI rats for 4 days. Cardiac performance and left ventricular remodeling were evaluated using ultrasonography and immunostaining. BM-MSC recruitment to damaged tissue in green fluorescent protein-bone marrow transplantation (GFP-BMT) models was evaluated using immunostaining.
At four weeks post-treatment, the left ventricular ejection fraction was significantly improved in the HMGB1 group compared to that in the control. Interstitial fibrosis and cardiomyocyte hypertrophy were also significantly attenuated in the HMGB1 group compared to the control. In the peri-infarction area, VEGF-A mRNA expression was significantly higher and TGFβ expression was significantly attenuated in the HMGB1 group than in the control. In GFP-BMT rats, GFP+/PDGFRα+ cells were significantly mobilized to the peri-infarction area in the HMGB1 group compared to that in the control, leading to the formation of new vasculature. In addition, intravital imaging revealed that more GFP+/PDGFRα+ cells were recruited to the peri-infarction area in the HMGB1 group than in the control 12 h after treatment.
Systemic administration of HMGB1 induced angiogenesis and reduced fibrosis by recruiting PDGFRα+ mesenchymal cells from the bone marrow, suggesting that HMGB1 administration might be a new therapeutic approach for heart failure after MI.
高迁移率族蛋白 B1 片段(HMGB1)可增强骨髓间充质干细胞(BM-MSC)向受损组织的募集,从而促进组织再生。本研究旨在评估系统给予 HMGB1 片段是否能促进心肌梗死(MI)大鼠模型中的组织修复。
将 HMGB1(n=14)或磷酸盐缓冲盐水(n=12,对照组)给予 MI 大鼠,连续给药 4 天。使用超声心动图和免疫染色评估心脏功能和左心室重构。使用 GFP 骨髓移植(GFP-BMT)模型评估 BM-MSC 向受损组织的募集情况。
治疗 4 周后,与对照组相比,HMGB1 组的左心室射血分数明显提高。与对照组相比,HMGB1 组的间质纤维化和心肌细胞肥大也明显减轻。在梗死周边区,HMGB1 组的 VEGF-A mRNA 表达明显升高,TGFβ 表达明显降低。在 GFP-BMT 大鼠中,与对照组相比,HMGB1 组 GFP+/PDGFRα+细胞明显向梗死周边区募集,形成新的血管。此外,活体成像显示,与对照组相比,治疗 12 小时后,HMGB1 组有更多的 GFP+/PDGFRα+细胞募集到梗死周边区。
系统给予 HMGB1 通过从骨髓募集 PDGFRα+间充质细胞诱导血管生成并减少纤维化,提示 HMGB1 给药可能是 MI 后心力衰竭的一种新的治疗方法。